Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
28 Marzo 2023 - 2:30PM
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology
company dedicated to discovering and developing transformative
treatments to restore and improve hearing and balance, today
announced that Laurence Reid, Ph.D., Chief Executive Officer, will
participate in a fireside chat at the Guggenheim Healthcare Talks |
Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at
9:00 a.m. E.T in New York, NY.
A live webcast of the presentation may be accessed
by visiting the Investors section of the Decibel Therapeutics
website at https://ir.decibeltx.com. An archived replay of the
webcast will be available on the Company’s website for
approximately 90 days following the fireside chat.
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage
biotechnology company dedicated to discovering and developing
transformative treatments to restore and improve hearing and
balance, one of the largest areas of unmet need in medicine.
Decibel has built a proprietary platform that integrates
single-cell genomics and bioinformatic analyses, precision gene
therapy technologies and expertise in inner ear biology. Decibel is
leveraging its platform to advance gene therapies designed to
selectively replace genes for the treatment of congenital,
monogenic hearing loss and to regenerate inner ear hair cells for
the treatment of acquired hearing and balance disorders. Decibel’s
pipeline, including its lead gene therapy program, DB-OTO, to treat
congenital, monogenic hearing loss, is designed to deliver on our
vision of a world in which the privileges of hearing and balance
are available to all. For more information about Decibel
Therapeutics, please visit www.decibeltx.com or follow us on
Twitter.
Investor Contact:Julie SeidelStern
Investor Relations, Inc.julie.seidel@sternir.com212-362-1200
Media Contact:Chris RaileyTen
Bridge
CommunicationsChris@tenbridgecommunications.com617-834-0936
Decibel Therapeutics (NASDAQ:DBTX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Decibel Therapeutics (NASDAQ:DBTX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024